FDA Approves New GIST Rx
The US Food and Drug Administration has approved a medication to treat gastrointestinal stromal tumors (GIST) that can’t be removed with surgery, have spread or no longer respond to existing therapies.
Longer Drug Treatments for GI Cancer?
Newly published studies have begun to emphasize the effectiveness of combining several types of treatment for the best success in cancer therapy. This includes patients with gastrointestinal stromal cancers (GIST).
FDA Approves Gleevec for Rare Gastrointestinal Cancer
The U.S. Food and Drug Administration granted Gleevec ( imatinib ) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today’s action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the standard 12 months of treatment.